Erythema Toxicum Neonatorum in Newborns and the Development of Asthma - Full Text View

Erythema Toxicum Neonatorum in Newborns and the Development of Asthma

This study is ongoing, but not recruiting participants.

Sponsored by:	University of Rochester
Information provided by:	University of Rochester
ClinicalTrials.gov Identifier:	NCT00178152

Purpose

Erythema Toxicum Neonatorum (ETN) is a common skin finding that affects healthy full-term babies. Several authors have commented on the possible relationship between ETN and the development of atopic conditions, such as atopic dermatitis or respiratory disease later in life. There is a paucity of research addressing this issue.

Condition

Asthma
Erythema Toxicum Neonatorum

MedlinePlus related topics:

Asthma

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control, Retrospective

Official Title:	The Implication of Erythema Toxicum Neonatorum in Newborns on the Development of Future Asthma

Further study details as provided by University of Rochester:

Biospecimen Retention: None Retained

Biospecimen Description:

Enrollment:	334
Study Start Date:	May 2005

Eligibility

Ages Eligible for Study:	3 Years to 9 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Case studies will include subjects between the ages of 3-9 years who have had at least 2 asthma diagnoses within the last 2 years. Patients will be selected based upon their ICD9 codes for asthma. Control subjects will be age matched and without an asthma diagnosis.

Criteria

Inclusion Criteria:

Children between the ages of 3-9 years who have had at least 2 asthma diagnoses within the last 2 years.
Control subjects will be age matched and without an asthma diagnosis.

Exclusion Criteria:

Children without accessible medical records

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00178152

Locations


United States, New York
	Strong Pediatric Practice, University of Rochester
	Rochester, New York, United States, 14642

Sponsors and Collaborators

University of Rochester

Investigators


Principal Investigator:	Jill S Halterman, MD, MPH	University of Rochester

Study Chair:	Ritu Pabby, MD	Allegheny General Hospital

More Information

Responsible Party:	University of Rochester ( Jill S. Halterman, MD, MPH )
Study ID Numbers:	00011627
First Received:	September 12, 2005
Last Updated:	December 20, 2007
ClinicalTrials.gov Identifier:	NCT00178152
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Hypersensitivity

Lung Diseases, Obstructive

Erythema

Skin Diseases

Respiratory Tract Diseases

Lung Diseases

Hypersensitivity, Immediate

Asthma

Respiratory Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases

Bronchial Diseases

ClinicalTrials.gov processed this record on October 17, 2008